Safety and Immunogenicity of Recombinant Zoster Vaccine for Transplant Recipients

The goal of this clinical trial is to compare responses to Varicella Zoster vaccination between transplant patients on different medication regimens, and their healthy co-habitants. The main questions it aims to answer are: 1. Are there differences in vaccination immunological responses in transplant patients on different immunosuppression regimens? 2. Are there differences in vaccination immunological responses between transplant patients and their healthy co-habitants? Participants will all receive a 2-dose course of SHINGRIX recombinant Zoster vaccination, and have immunological responses measured and compared at 5 timepoints between 1 week to 1 year post-vaccination.

NCT Number	NCT06262776
Lead Sponsor	Central Adelaide Local Health Network Incorporated Collaborators: National Health and Medical Research Council, Australia, University of Adelaide, Royal Prince Alfred Hospital, Sydney, Australia
Conditions	Immunosuppression, Vaccine Response Impaired
Enrollment	160 participants
Start Date	2024-03-20
Primary Completion	2026-12 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2026-04-09